Flip a coin until you get tails. This attack does 30 damage times the number of heads or you may start again. Each time you start again, put 2 damage counters on Mamoswine. (If Mamoswine would be Knocked Out, you can't start again.)
Does 60 damage plus 10 more damage for each Swinub on your Bench, plus 20 more damage for each Piloswine on your Bench, and 40 more damage for each Mamoswine on your Bench.
Stormfront entered circulation in 2008. It belongs to the Diamond & Pearl series.
The checklist contains 106 cards, placing it in a mid-size expansion range. As of 2026, the set is 18 years old and fits a legacy-era profile.
Mamoswine (#21) is one of the Rare prints in this expansion.
Mamoswine appears in Stormfront, released in 2008. Its card type is Pokémon.
The rarity label is Rare. Printed HP is 140.
Energy typing is Fighting. This card evolves from Piloswine.
Attack line includes "Ramming Strike" and "Parade". This card is weak to Grass energy and resists Lightning.
Mamoswine (Stormfront) is presently valued at about $1.13 in raw condition. The 7-day delta remains near neutral at 0.0%.
Current value is elevated versus the 30-day mean ($1.10), by 2.5%. In the past 90 days, observed prices ranged from $1.01 to $1.13 (11% spread), a low-volatility profile.
This version is categorized as Rare.
A wider Mamoswine checklist helps contextualize this specific Mamoswine print. The current sample spans 6 comparable cards from 6 sets.
In this sample, pricing ranges between $0.08 and $1.64 (1950% total span). Relative to the alternative average ($0.70), this card is +62%.
Notable alternatives include Mamoswine #25 (Phantasmal Flames) at $0.08, Mamoswine #82 (BREAKthrough) at $0.84, Mamoswine #33 (Astral Radiance) at $0.14, and Mamoswine #21 (Crimson Invasion) at $0.22.
Market structure summary: Over the last 7 days, prices have remained stable at 0.0%, indicating a consolidation phase over sudden breakouts. The 90-day range spans $1.01 to $1.13 (11% spread), which indicates low-volatility behavior.
Relative to the 30-day baseline ($1.10), pricing is near equilibrium. Graded comparison currently centers on PSA 9 near $30.00, representing +2555% over raw value.
